Beniag — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Beniag is a private, pre-revenue platform company pioneering a novel, patented transfection technology based on direct liposome-to-cell membrane fusion. Its Fuse-It products are designed to deliver diverse molecular payloads—including plasmid DNA—into virtually any mammalian cell type with exceptional speed (seconds to minutes) and high efficiency (80-100%), while minimizing off-target effects. Operating from Munich, the company targets the life sciences research tools market, offering a versatile alternative to traditional delivery methods like lipofection or electroporation.

Drug Delivery

Technology Platform

Patented membrane fusion technology using specially formulated liposomal carriers that fuse directly with the plasma membrane of mammalian cells, enabling rapid, high-efficiency delivery of diverse molecular payloads independent of biological uptake mechanisms.

Opportunities

The global transfection and cell manipulation market offers significant growth potential, driven by R&D in gene function studies, bioproduction, and cell therapy.

Beniag's technology, with its claimed advantages in speed, efficiency, and versatility, is well-positioned to capture share from incumbent methods, particularly for difficult-to-transfect cell types and sensitive applications like primary cell engineering.

Risk Factors

Key risks include the need for broad independent validation of its performance claims, intense competition from large, established life science tools companies, and the inherent challenge of driving adoption of a novel technology among conservative researchers.

As a small, private company, it also faces execution and funding risks.

Competitive Landscape

Beniag competes in the crowded transfection reagents market dominated by giants like Thermo Fisher Scientific, Merck KGaA, and Bio-Rad. Its differentiation is based on a novel fusion mechanism versus standard lipofection or polymer-based transfection, claiming superior speed and efficiency. It also competes with electroporation systems, offering a potentially gentler and more scalable solution.

More companies in Germany →